Assessments
About Biophysical250
Know more for less
Superior, personalized service
Proven technology
The process
Testimonials
FAQ
Security and Privacy
Proven Technology
Proven in the pharmaceutical industry, now available to consumers
Through the innovative use of technology developed for clinical researchers and the pharmaceutical industry, Biophysical250 now offers consumers a means to have their own personal health risk factors evaluated. Many diseases or medical conditions alter the level of an individual's specific blood chemistry in a characteristic fashion. Tests that detect these changes are cornerstones of modern medicine. Biophysical250 is an assessment tool that provides the single most comprehensive evaluation of an individual's health.
State-of-the-art health surveillance
This assessment measures 250 different biomarkers that may indicate the presence of many conditions and diseases, including cancer, cardiovascular disease, metabolic disorders, autoimmune disease, viral and bacterial diseases and hormonal imbalance. This biochemical profile includes the measurement of blood components whose affect on health is broadly recognized, as well as those recognized only by clinical specialists.
The Biophysical250 panel is comprised of approximately 60 biomarkers commonly used in general medicine, 80 biomarkers used in 12 medical specialties and 110 biomarkers that are primarily used in medical research.
In addition, the assessment provides a valuable baseline enabling individuals and physicians to monitor changes and trends in blood chemistry over time.
Biophysical250 biomarker panel
Why analyze or "stack" multiple biomarkers?
There may be a significant benefit in simultaneously measuring multiple biomarkers (a process also called “stacking”). For example, the most commonly used screening test for ovarian cancer is a single biomarker called CA 125. However, CA 125 only identifies Stage I ovarian cancer in 50 percent of cases. The other half of women with early stage cancer will be missed by this single test. If five additional, biologically independent tests, each of which also has an individual detection rate of only 50 percent, are stacked along with the CA 125 test, the theoretical combined detection rate of the six tests increases to 98 percent.
Source: Hematology/Oncology Clinics of North America
Volume 17. Number 4. August 2003
Biophysical250 was developed by an expert team of researchers and doctors who have spent years developing advanced testing technologies for hospitals, universities and pharmaceutical companies around the world. Our medical advisory board includes internationally renowned physicians and scientists from leading medical institutions.
Disclaimer: Biophysical250 results do not constitute a medical opinion or advice. These results are not medical care, treatment, a treatment recommendation or a diagnosis. Communication with medical professionals employed by Biophysical Corporation about the Biophysical250 or its results does not establish a physician-patient relationship.